Paclitaxel Novaplus and Sorafenib Tosylate

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using SORAfenib together with PACLitaxel may increase the blood levels of both medications. This may increase the risk of side effects such as anemia, bleeding problems, infections, high blood pressure, irregular heart rhythm, chest pain, skin rash/peeling (especially the hands and feet), diarrhea, and loss of appetite. Contact your doctor if your condition changes or you experience increased side effects. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Concomitant administration of paclitaxel and sorafenib may increase the plasma concentrations of both drugs. The mechanism by which paclitaxel increases sorafenib exposure is unknown; sorafenib may increase paclitaxel exposure by inhibiting its metabolism via the CYP450 2C8 enzymatic pathway. When paclitaxel (225 mg/m2) and carboplatin (AUC=6 mg/ml min) once every 3 weeks were given with sorafenib (400 mg twice daily), there was a 47% increase in sorafenib systemic exposure (AUC) and a 29% and 50% increase in the AUC of paclitaxel and 6-hydroxypaclitaxel, respectively. The pharmacokinetics of carboplatin were unaffected. When paclitaxel and carboplatin were administered following a 3-day break in sorafenib dosing (two days prior to and on the day of paclitaxel/carboplatin administration), no significant effect on the pharmacokinetics of paclitaxel was observed.

MANAGEMENT: Caution is advised during the concomitant use of paclitaxel and sorafenib. Close monitoring for toxicities of paclitaxel (e.g., bone marrow suppression, especially neutropenia; conduction abnormalities; peripheral neuropathy) and sorafenib (e.g., rash/desquamation; hand-foot skin reaction; hypertension; hemorrhage; cardiac ischemia; myocardial infarction; QT prolongation; diarrhea; anorexia; gastrointestinal perforation; wound healing complications) is recommended, and the dosage of each drug adjusted as necessary. No dosage adjustment should be needed when paclitaxel is coadministered with sorafenib following a 3-day break in sorafenib dosing.

Paclitaxel Novaplus

Generic Name: paclitaxel

Brand name: Onxol, Taxol

Synonyms: Paclitaxel, PACLitaxel (Conventional)

What is Paclitaxel Novaplus?

Sorafenib Tosylate

Generic Name: sorafenib

Brand name: Nexavar

Synonyms: Sorafenib, SORAfenib

What is Sorafenib Tosylate?